AInvest Newsletter
Daily stocks & crypto headlines, free to your inbox
_6ff029a61766633234293.png?format=webp&width=1186&height=250)
Hologic Shares Surge 7.7% Amid Reports of New Acquisition Offer
ByAinvest
Thursday, Sep 18, 2025 10:57 am ET1min read
Hologic Inc. (NASDAQ:HOLX) shares jumped 7.69% to $68.20 on Wednesday amid reports of a renewed $16.7 billion takeover bid from Blackstone and TPG. The company has raised its revenue forecast for FY2025 to $4.08-$4.09 billion and expects Q4 revenues to hit $1.03-$1.04 billion.
Hologic Inc. (NASDAQ:HOLX) shares jumped 7.69% to $68.20 on Wednesday amid reports of a renewed $16.7 billion takeover bid from Blackstone and TPG. The medical device maker's stock has been an attractive acquisition target due to its recent stock performance challenges and the potential strategic value of its women's health products [1].The investment firms have re-engaged with Hologic’s board about a potential takeover and are currently conducting due diligence, according to Bloomberg. This renewed interest comes after the Financial Times reported in May that Blackstone and TPG had approached Hologic with an offer exceeding $16 billion, which was rejected at the time [1].
Despite the positive news, Hologic remains down 16.8% over the past 12 months. However, the company's stock has shown resilience, with several analysts maintaining a positive outlook. Hologic received an average "Moderate Buy" rating and a price target of $78.00, according to data from MarketBeat [2].
The company reported earnings of $1.08 per share for the last quarter, surpassing expectations, with revenue increasing by 1.2% year-over-year. Hologic's quarterly revenue was up 1.2% on a year-over-year basis, and the company has set its Q4 2025 guidance at 1.090-1.120 EPS. The FY 2025 guidance is at 4.230-4.260 EPS [2].
Institutional investors have also shown interest in Hologic. United Services Automobile Association bought a new stake in shares of Hologic during the first quarter, valued at approximately $347,000. Other hedge funds and institutional investors own 94.73% of the company's stock [3].
The renewed takeover interest and positive earnings reports suggest that Hologic may be on the path to recovery. However, any potential deal is still weeks away and there’s no certainty the talks will result in a transaction. Hologic and the investment firms have not publicly commented on the renewed takeover interest [1].
Ainvest News articles are AI-generated using advanced large language model (LLM) technology designed to analyze and synthesize publicly available data and news. While AI tools assist in producing initial drafts and insights, all AI generated content published on Ainvest is subject to comprehensive human editorial review before publication. A designated human editor reviews, verifies, and approves each article for factual accuracy, coherence, and compliance with AInvest Fintech Inc’s editorial and disclosure standards.
Despite these review procedures, the information provided may still contain inaccuracies, incomplete data, or time sensitive references due to the inherent limitations of AI generated analysis and evolving changes. The material is provided strictly for informational and educational purposes and does not constitute personalized investment, legal, or financial advice. Readers should independently verify all facts, figures, and statements before making any decision based on this content.
AInvest Fintech Inc. its affiliates, and partners accept no liability or responsibility for any direct or consequential losses arising from reliance on this content. All articles and analyses are subject to revision, update, or removal without prior notice to maintain accuracy and integrity in our publications.
Comments
No comments yet